Pharmaceutical / Drug Definition :
Decreases blood glucose level by stimulating insulin secretion from pancreatic beta cells; interacts with calcium and potassium channels in pancreas
FDA Detentions
Nateglinide (Nateglinide Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Nateglinide (Nateglinide Suppliers)
- Processors Nateglinide
- Repackers Nateglinide
- Relabelers Nateglinide
- Exporters Nateglinide
- Importers Nateglinide
For more information about Nateglinide, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.
